Compared to s.c. or i.m. vaccination, i.v. administration resulted in an increased frequency of Tc1 and CD4+ T helper cells in the tumor and spleen, as well as a higher ratio of CD8+ T cells to CD4+ T helper cells in the blood, suggesting successful T‐cell activation. Here, CD8A is linked to neoplasm.